Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin

Bandekar, Amey; Karve, Shrirang; Chang, Min-Yuan; Mu, Qingshan; Rotolo, Jimmy A.; Sofou, Stavroula

doi:10.1016/j.biomaterials.2012.02.039

Cited by 39 publications

(37 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This amount of PEG on the surface of AuNPs could improve the colloid stability and prevent the serum protein adsorption [32,38]. The DOX loading capacity of AuNPs was approximately 9.7%, which was much higher than other organic nanoparticles [39,40].…”

Section: Characterization Of Gold Nanoparticlesmentioning

confidence: 98%

Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles

et al. 2015

View full text Add to dashboard Cite

Section: Characterization Of Gold Nanoparticlesmentioning

confidence: 98%

Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles

et al. 2015

View full text Add to dashboard Cite

“…Herceptin molecule or its fragments (Fab or ScFv) have been also used to decorate nanoparticles or liposomes for the selective delivery of anticancer drugs such as doxorubicin 4 or paclitaxel 5 to HER-2-positive tumors. Compared with large molecules such as antibodies and their derivatives, smaller peptide molecules appear to be more attractive targeting moieties because of their less expensive and simple production, lack of immunogenicity, chemical stability, and flexibility in the choice of conjugation procedures to the carrier's surface.…”

Section: Ringhieri Et Almentioning

confidence: 99%

“…Fmoc-l-propargylglycine (Fmoc-Pra-OH) was bought from Neosystem (Strasbourg, France). The 14-azido-5-oxo-3,9,12-trioxa-6-azatetradecan-1-oic acid (N 3 -Peg(9)-COOH) was bought from Iris Biotech GmbH (Marktredwitz, Germany), and diethylenetriamine-N,N,N″,N″-tetra-tertbutyl acetate-N′-acetic acid [DTPA(OtBu) 4 ] was bought from CheMatech (Dijon, France). DOPC and 1,2-dioleoylsn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rho-PE) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).…”

Section: Materials and Instrumentationmentioning

confidence: 99%

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells

Ringhieri¹,

Mannucci²,

Conti³

et al. 2017

IJN

View full text Add to dashboard Cite

Mixed liposomes, obtained by coaggregation of 1,2-dioleoyl-sn-glycero-3-phosphocholine and of the synthetic monomer containing a gadolinium complex ([C18]2DTPA[Gd]) have been prepared. Liposomes externally decorated with KCCYSL (P6.1 peptide) sequence in its monomeric, dimeric, and tetrameric forms are studied as target-selective delivery systems toward cancer cells overexpressing human epidermal growth factor receptor-2 (HER-2) receptors. Derivatization of liposomal surface with targeting peptides is achieved using the postmodification method: the alkyne-peptide derivative Pra-KCCYSL reacts, through click chemistry procedures, with a synthetic surfactant modified with 1, 2, or 4 azido moieties previously inserted in liposome formulation. Preliminary in vitro data on MDA-MB-231 and BT-474 cells indicated that liposomes functionalized with P6.1 peptide in its tetrameric form had better binding to and uptake into BT-474 cells compared to liposomes decorated with monomeric or dimeric versions of the P6.1 peptide. BT-474 cells treated with liposomes functionalized with the tetrameric form of P6.1 showed high degree of liposome uptake, which was comparable with the uptake of anti-HER-2 antibodies such as Herceptin. Moreover, magnetic MRI experiments have demonstrated the potential of liposomes to act as MRI contrast agents

show abstract

“…60 In addition, in murine xenograft models, lipid vesicles with DOX-loaded pHtriggered anti-HER2/neu cells showed a greater reduction in tumor volume compared with FDA-approved DOX-loaded vesicles. 61 However, the clinical application of lipid vesicles or liposomes requires optimization in terms of both size and surface to resolve some of their disadvantages, such as their rapid renal clearance, recognition by the reticuloendothelial system, or low penetration in tumors. By contrast, polymeric NPs similar to those used here have already demonstrated a homogeneous size, a greater ability to solubilize hydrophobic drugs, a sustained release of the drug plus highly stable and customizable physicochemical properties, which means they will be accepted for clinical use in the near future.…”

mentioning

confidence: 99%

Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

Cabeza¹,

Ortíz²,

Arias³

et al. 2015

IJN

View full text Add to dashboard Cite

The use of doxorubicin (DOX), one of the most effective antitumor molecules in the treatment of metastatic breast cancer, is limited by its low tumor selectivity and its severe side effects. Colloidal carriers based on biodegradable poly(butylcyanoacrylate) nanoparticles (PBCA NPs) may enhance DOX antitumor activity against breast cancer cells, thus allowing a reduction of the effective dose required for antitumor activity and consequently the level of associated toxicity. DOX loading onto PBCA NPs was investigated in this work via both drug entrapment and surface adsorption. Cytotoxicity assays with DOX-loaded NPs were performed in vitro using breast tumor cell lines (MCF-7 human and E0771 mouse cancer cells), and in vivo evaluating antitumor activity in immunocompetent C57BL/6 mice. The entrapment method yielded greater drug loading values and a controlled drug release profile. Neither in vitro nor in vivo cytotoxicity was observed for blank NPs. The 50% inhibitory concentration (IC 50 ) of DOX-loaded PBCA NPs was significantly lower for MCF-7 and E0771 cancer cells (4 and 15 times, respectively) compared with free DOX. Furthermore, DOX-loaded PBCA NPs produced a tumor growth inhibition that was 40% greater than that observed with free DOX, thus reducing DOX toxicity during treatment. These results suggest that DOX-loaded PBCA NPs have great potential for improving the efficacy of DOX therapy against advanced breast cancers.

show abstract

Antitumor efficacy following the intracellular and interstitial release of liposomal doxorubicin

Cited by 39 publications

References 41 publications

Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles

Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles

Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells

Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles

Contact Info

Product

Resources

About